AR122353A1 - Formas farmacéuticas sólidas que contienen bacterias y vesículas extracelulares microbianas - Google Patents

Formas farmacéuticas sólidas que contienen bacterias y vesículas extracelulares microbianas

Info

Publication number
AR122353A1
AR122353A1 ARP200103650A ARP200103650A AR122353A1 AR 122353 A1 AR122353 A1 AR 122353A1 AR P200103650 A ARP200103650 A AR P200103650A AR P200103650 A ARP200103650 A AR P200103650A AR 122353 A1 AR122353 A1 AR 122353A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical agent
capsule
extracellular vesicles
coated
preparing
Prior art date
Application number
ARP200103650A
Other languages
English (en)
Inventor
Christopher J H Davitt
Brian Goodman
Syed Altaf
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AR122353A1 publication Critical patent/AR122353A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan formas farmacéuticas sólidas recubiertas entéricamente que contienen un agente farmacéutico que incluye bacterias y/o Vesículas Extracelulares microbianas (VEm). También se proporcionan métodos de tratamiento que utilizan tales formas farmacéuticas sólidas. Reivindicación 1: Una forma farmacéutica sólida que comprende un agente farmacéutico, donde el agente farmacéutico comprende bacterias y/o vesículas extracelulares microbianas (VEm), y donde la forma farmacéutica sólida está recubierta entéricamente. Reivindicación 112: Un método para preparar una cápsula recubierta entéricamente que comprende un agente farmacéutico, donde el agente farmacéutico comprende bacterias y/o vesículas extracelulares microbianas (VEm), comprendiendo el método: a) combinar el agente farmacéutico con un excipiente farmacéuticamente aceptable; b) cargar el agente farmacéutico y el excipiente farmacéuticamente aceptable en una cápsula; y c) recubrir entéricamente la cápsula, preparando así la cápsula recubierta entéricamente. Reivindicación 118: Un método para preparar una cápsula que comprende minicomprimidos recubiertos entéricamente que comprenden un agente farmacéutico, donde el agente farmacéutico comprende bacterias y/o vesículas extracelulares microbianas (VEm), comprendiendo el método: a) combinar el agente farmacéutico con un excipiente farmacéuticamente aceptable; b) comprimir el agente farmacéutico y el excipiente farmacéuticamente aceptable, formando así un minicomprimido; c) recubrir entéricamente el minicomprimido, preparando así un minicomprimido recubierto entéricamente; y d) cargar la cápsula con uno o más minicomprimidos recubiertos entéricamente, preparando así la cápsula.
ARP200103650A 2019-12-27 2020-12-23 Formas farmacéuticas sólidas que contienen bacterias y vesículas extracelulares microbianas AR122353A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962954153P 2019-12-27 2019-12-27

Publications (1)

Publication Number Publication Date
AR122353A1 true AR122353A1 (es) 2022-09-07

Family

ID=74626080

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103650A AR122353A1 (es) 2019-12-27 2020-12-23 Formas farmacéuticas sólidas que contienen bacterias y vesículas extracelulares microbianas

Country Status (13)

Country Link
US (1) US20230355689A1 (es)
EP (1) EP4081195A1 (es)
JP (1) JP2023510158A (es)
KR (1) KR20220128362A (es)
CN (1) CN114945357A (es)
AR (1) AR122353A1 (es)
AU (1) AU2020413225A1 (es)
BR (1) BR112022012514A2 (es)
CA (1) CA3165418A1 (es)
CO (1) CO2022010242A2 (es)
MX (1) MX2022007943A (es)
TW (1) TW202135783A (es)
WO (1) WO2021133904A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp
EP4185307A1 (en) * 2020-07-21 2023-05-31 Evelo Biosciences, Inc. Veillonella parvula strain as an oral therapy for neuroinflammatory diseases
WO2023049268A1 (en) * 2021-09-24 2023-03-30 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2023113541A1 (en) * 2021-12-16 2023-06-22 Enterobiome Inc. Pharmaceutical composition for preventing or treating cancer or inflammatory disease
CN115252651B (zh) * 2022-06-08 2024-06-07 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物
WO2024050289A1 (en) * 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
CN116509900B (zh) * 2022-12-01 2023-11-10 佛山科学技术学院 益生菌或其细胞外囊泡在制备防治胃溃疡产品中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5292522A (en) 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
US5047258A (en) 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19631084A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
DE19937361A1 (de) * 1999-08-12 2001-02-22 Merck Patent Gmbh Orale Darreichungsform
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
DE10260919A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
US20070065513A1 (en) 2003-10-31 2007-03-22 Avi Avramoff Stable lansoprazole formulation
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
CN101209247B (zh) * 2006-12-27 2011-12-14 天津中新药业集团股份有限公司 一种结肠靶向制剂的制备方法
CN101757042A (zh) * 2009-05-25 2010-06-30 北京诚创康韵医药科技有限公司 一种益生菌微丸制剂及其制备
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN105142616B (zh) 2013-03-01 2018-02-13 Bpsi控股有限责任公司 含有硅酸钙的延迟释放薄膜包衣及其包被的底物
JP6464142B2 (ja) * 2013-03-14 2019-02-06 セラバイオーム，エルエルシー プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー

Also Published As

Publication number Publication date
TW202135783A (zh) 2021-10-01
AU2020413225A1 (en) 2022-06-23
CO2022010242A2 (es) 2022-10-21
KR20220128362A (ko) 2022-09-20
MX2022007943A (es) 2022-07-27
WO2021133904A1 (en) 2021-07-01
BR112022012514A2 (pt) 2022-09-06
JP2023510158A (ja) 2023-03-13
CN114945357A (zh) 2022-08-26
EP4081195A1 (en) 2022-11-02
US20230355689A1 (en) 2023-11-09
CA3165418A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
AR122353A1 (es) Formas farmacéuticas sólidas que contienen bacterias y vesículas extracelulares microbianas
MX2021009475A (es) Composiciones farmaceuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MX2022013410A (es) Metodos de tratamiento.
SG10201807070YA (en) Respiratory mask with nasogastric tube path
WO2015020943A3 (en) Digestive enzyme composition suitable for enteral administration
MY189306A (en) Tablet
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
WO2017053732A3 (en) Composition and method for treating complement-mediated disease
PH12021550713A1 (en) Medicament for the treatment of chronic cough
BR112015032728A2 (pt) formulação compósita em cápsula farmacêutica compreendendo tadalafil e tansulosina
EP4252847A3 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
CR20220355A (es) Compuestos activos frente a receptores nucleares
MX2020008028A (es) Terapia de combinacion para cancer con complejo de anillo macrociclico de pentaaza y agente anticancer basado en platino.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
CL2016001801A1 (es) Proceso para la reconstitución de una forma sólida de una composición farmacéutica.
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
CO2021016606A2 (es) Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple
BR112022006342A2 (pt) Composição inovadora de cuidados com a pele
MX2021003033A (es) Formulaciones de compuestos de cicloserina y aplicaciones de estas.
MX2022004050A (es) Composicion novedosa para el cuidado de la piel.
AR127111A1 (es) Formas farmacéuticas sólidas que contienen bacterias y vesículas extracelulares microbianas
CY1125250T1 (el) Εντερικο επικαλυμμενο χορηγουμενο απο το στομα φαρμακευτικο παρασκευασμα που περιλαμβανει φουμαρικο διμεθυλεστερα
CO2021008688A2 (es) Fórmula de entrega de medicamentos colónicos
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
MX2021011314A (es) Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica.